ИСТИНА

Cerebral ischemia is a leading cause of disability worldwide. The search for new approaches to the treatment of acute ischemic stroke is one of the urgent problems of experimental and clinical neuroscience. It is known that erythropoietin (EPO) and its analogs exhibit pleiotropic hematopoietic effects, in particular cytoprotective properties in non-hematopoietic cells. A promising tendency in the development of new methods for medical treatment of ischemic conditions of the brain is to create drugs based on erythropoietin (EPO). Both carbamylated EPO (cEPO) and carbamylated dEPO (CdEPO) are one of the leading biopharmaceutical products attracting widespread interest due to their neuroprotective effects without erythropoiesis in several cells and animal models. [in vivo, in vitro] The neuroprotective effect of EPO derivatives can partly be realized through their preferential binding to the β-subunit of the receptor (βсR); thus, the process of signal transduction growth factors and cytokines starts (via the EPO receptor complex and CD131) [Brines M., 2004]. However, the molecular mechanism underlying the neuroprotective effects has to be investigated.